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OBJECTIVE: This research was designed as a pilot proof-of-concept study to evaluate the use of low-dose
methadone in post-herpetic neuralgia patients who remained refractory after first and second line post-
herpetic neuralgia treatments and had indications for adding an opioid agent to their current drug regimens.
METHODS: This cross-over study was double blind and placebo controlled. Ten opioid naı¨ve post-herpetic
neuralgia patients received either methadone (5 mg bid) or placebo for three weeks, followed by a 15-day
washout period and a second three-week treatment with either methadone or placebo, accordingly. Clinical
evaluations were performed four times (before and after each three-week treatment period). The evaluations
included the visual analogue scale, verbal category scale, daily activities scale, McGill pain questionnaire, adverse
events profile, and evoked pain assessment. All patients provided written informed consent before being
included in the study. ClinicalTrials.gov: NCT01752699
RESULTS: Methadone, when compared to placebo, did not significantly affect the intensity of spontaneous pain,
as measured by the visual analogue scale. The intensity of spontaneous pain was significantly decreased after the
methadone treatment compared to placebo on the category verbal scale (50% improved after the methadone
treatment, none after the placebo, p= 0.031). Evoked pain was reduced under methadone compared to placebo
(50% improved after the methadone treatment, none after the placebo, p= 0.031). Allodynia reduction
correlated with sleep improvement (r = 0.67, p= 0.030) during the methadone treatment. The side effects profile
was similar between both treatments.
CONCLUSIONS: Methadone seems to be safe and efficacious in post-herpetic neuralgia. It should be tried as an
adjunctive treatment for post-herpetic neuralgia in larger prospective studies.
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& INTRODUCTION
Methadone was first described over fifty years ago. It is a
synthetic opioid agonist that exhibits a potent antagonist
effect on glutamate N-methyl-D-aspartate (NMDA) recep-
tors. Methadone is highly bound to proteins (alfa-1-acid-
glycoprotein), highly lipophilic and metabolized by the liver
(mainly by the cytochrome P450 CYP 3A3/4 isoenzyme); it
has no known active metabolites. Methadone has a high
intestinal absorption, and its bioavailability is approximately
80%, with much less inter-individual variability compared to
other opioids, such as oral morphine. One unique feature of
methadone is that is has a robust distribution phase with a
short lasting (alpha) half-life of approximately 3 hours,
followed by an extended elimination phase (beta) ranging
from 12 to 60 hours; it also displays large inter-individual
variability. This elimination phase may result in toxicity and
drug accumulation. Most of the drug is excreted in feces with
no significant accumulation in patients with renal impair-
ment. Despite its long term use in drug addiction and in
cancer pain patients, there is a great paucity of studies on
methadone in neuropathic pain syndromes. Neuropathic
pain is present in 7% of the general population (1) and may
represent up to 60% of patients with cancer-related pain.
Opioids are effective for neuropathic pain and are used as
second and third line treatments in this population. However,
most of the available evidence concerns the use of tramadol
and extended release oxycodone. Other opioids, such as
hydromorphone and methadone, were seldom evaluated for
this pain syndrome.Methadone is an inexpensive andwidely
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available drug inmany countries, but it is also a potent NMDA
inhibitor, which could potentially increase its analgesic effects
in neuropathic pain patients. The aim of this pilot proof-of-
principle study was to evaluate the use of low-dose
methadone in refractory post-herpetic neuralgia (PHN)
patients who remained refractory after undergoing first and
second line treatments and had indications for adding an
opioid to their current drug regimen. The main outcome
measurement was pain intensity reduction, and the secondary
outcomes were patient safety, changes in pain interference in
daily life and the different effects of chronic pain.
& METHODS
Patients
The aim of this pilot proof-of-concept study was to assess
the safety and efficacy of methadone in PHN patients.
Patients with chronic (.6 months) symptomatic PHN with
visual analogical scale (VAS) scores .40/100 mm despite
using first and second line treatment drugs (e.g., tricyclic
antidepressants, venlafaxine and gabapentinoids) were
recruited from the Pain Center of the Hospital das
Clı´nicas, University of Sa˜o Paulo, Brazil. All patients were
opioid naı¨ve. The PHN diagnosis was based on current
diagnostic criteria (2) for defined neuropathic pain. Pain
was located in the cervical, dorsal or trigeminal areas.
The study was approved by our local institutional review
board and registered at ClinicalTrials.gov (0078/11 and
NCT01752699, respectively). All patients provided written
informed consent before being included in the study.
Study design
In this crossover, double-blind, randomized trial, all
participants received either methadone 5 mg or placebo
(bid) for three weeks, followed by a 3-week washout period
and then another three-week treatment period with metha-
done and placebo, according to the randomized treatment
sequence. The methadone and placebo pills looked identical.
Clinical assessment
All participants were evaluated before and after each
treatment period, for a total of four assessments (two at
baseline and two at the end of each three-week treatment
period). All clinical assessments were similar and included
the following details:
- spontaneous pain (SP) intensity using a VAS;
- evoked pain (EP), dynamic mechanical allodynia
intensity in the painful area was used to study EP,
and a gentle stroke with a standardized brush
(Senselab Brush 05, Somedic AB, Ho¨rby, Skane,
Sweden) at a speed of 2 cm/s and covering a 6-cm
distance inside the PHN painful area was used; EP
was scored as none ( = 0), mild ( = 1), moderate ( = 2), or
severe ( = 3) after three strokes;
- the Category Verbal Scale (CVS) was measured as
mild, moderate, and severe pain intensity (3);
- the daily activities scale (AS) (items from the Brief Pain
Questionnaire) was used to measure the impact of pain
on different activities of daily living and was scored as
normal ( = 0), decreased ( = 1), or abolished ( = 2) (4);
- the McGill Pain Questionnaire (MPQ) (5); and
- adverse events were assessed by direct questioning
patients on the presence of new symptoms presenting
during treatment.
Data analysis
Each participant’s baseline characteristics were expressed
as descriptive statistics with average ¡ standard deviation.
A non-parametric test for repeated series (the Wilcoxon
signed-rank test) was used because the data did not show
normal distribution according to the Kolmogorov-Smirnov
test. The proportion of responders vs. non-responders
and the total number of participants with improved or
aggravated symptoms (scores) under methadone compared
to placebo were compared using Fisher’s exact test.
Correlation analyses were performed using Spearman’s
correlation coefficient. Sample size was calculated based on
the data available on the effects of methadone in other
neuropathic pain syndromes (6,7). Sample size estimation
was calculated based on the information available from
open-label studies that suggested a responder rate close to
50% under methadone (6,8-10) In all instances, the level of
significance was set at p,0.05.
& RESULTS
Patient characteristics
Ten patients (6 females, mean age 71¡21 years) with
neuropathic pain secondary to PHN (mean duration of pain
Table 1 - Pain score and questionnaire comparisons between methadone and placebo.
Response to
methadone (n) Response to placebo (n)
Response to placebo
and to methadone (p-value)
Improvement in the Verbal Scale 5 0 5 0.031*
Reduction in the Visual
Analogue Scale
5 3 2 0.363
Improvement in Evoked Pain 5 0 5 0.031*
MPQ subscores
Sensitive 7 3 0 0.172
Affective 3 4 3 0.773
Evaluative 2 4 4 0.890
Miscellaneous 2 6 2 0.964
Total number of responders in each treatment arm (methadone and placebo). The results are expressed as the total number of responders. Improvement
in the verbal scale pain score from baseline; VAS, visual analogue scale, $30% reduction from baseline; Evoked pain improvement, pain intensity
reduction ($30%) from baseline.
McGill Pain Questionnaire (MPQ), subscores of the different aspects of pain (sensitive, evaluative, affective and miscellany), $3 decreases in each domain
from baseline. *p,0.05.
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41¡19 months) were included in the study and completed
the two treatment phases. They experienced pain in the
following dermatomes/areas: cervical n = 3, dorsal n = 4,
and trigeminal n = 3.
The treatment had the following effects on the patients’
pain and general activity levels.
Methadone did not significantly affect the intensity of
spontaneous pain, as measured by the VAS compared to
placebo.
The intensity of spontaneous pain was significantly
decreased after the methadone treatment compared to
placebo on the CVS (50% improved after methadone, none
after placebo, p= 0.031). EP was reduced with methadone
compared to placebo (50% improved after methadone, none
after placebo, p= 0.031) (Table 1).
The activities of daily living and McGill Pain
Questionnaire scores did not significantly change after the
active treatment. In particular, methadone did not have any
negative impact on daily activities, such as concentration,
mood or sleep.
Correlation analyses
Allodynia reduction correlated with sleep improvement
(r = 0.67, p= 0.030) during the methadone treatment. Older
age was associated with greater impacts on concentration
(r = -0.69, p= 0.024) and daily activities (r = 0.69, p= 0.025).
Side effects
The frequency of reported adverse events, such as
constipation, nausea and dizziness, did not differ signifi-
cantly in either treatment period. None of the participants
left the study.
& DISCUSSION
We have demonstrated that at low doses, methadone
decreased the pain intensity scores and evoked pain levels
in PHN patients and had a satisfactory safety profile. This
controlled study is one of the few to study methadone’s
effect on neuropathic pain and the only one to evaluate a
specific patient group, such as PHN patients.
There is a great paucity of randomized controlled studies
of methadone in chronic pain. Note, there are no placebo-
controlled studies on the use of this drug in cancer patients,
which is understandable because of ethical issues. Case
series have suggested that methadone could be used long
term in neuropathic pain patients (11,12). Until now, only one
placebo controlled study evaluated its efficacy in a small
sample of heterogeneous neuropathic pain syndromes (13).
In this study, methadone was used in a rather peculiar
regimen, taken on alternate days at 10 and 20 mg/day doses.
It was found that methadone at 20 mg/day had a significant
effect over placebo in each 20-day trial duration (7). An open-
label study evaluated the analgesic effect of methadone
against morphine in cancer pain patients. The analgesic
effects were similar, but methadone was associated with less
frequent dry mouth andmore frequent headaches, and while
the morphine dose had to be significantly titrated during the
14-day trial, the methadone dose remained the same (14).
Similar results were reported (15) in a parallel trial compar-
ing methadone and morphine in cancer pain patients. In a
more recent study (16), the authors suggested that metha-
done would be as effective as morphine in cancer pain
patients with or without neuropathic pain. However, the
external validity of this study remained limited because of
the extremely high drop-out rate observed, which was most
likely caused by the high dose conversion ratio from
morphine to methadone (2:1) and the fixed dose regimen
chosen, which would force patients in the methadone group
to receive relatively more drug than the morphine arm, with
no possibility to decrease it without leaving the study.
The latest study (17) included cancer pain patients in an
open-label parallel design trial to receive either methadone,
sustained release morphine or transdermal fentanyl. The
authors found no difference in pain relief or in the negative
impacts of quality of life or adverse events. However,
methadone was associated with a substantially lower
treatment cost than the other treatments.
Excitatory amino acids have been implicated in the
occurrence of neuropathic pain, specifically through
NMDA receptors, which have been implicated in the
occurrence of opioid tolerance and are considered to play
a major role in the central sensitization seen in neuropathic
pain patients. Because methadone is a potent opioid agonist
and an NMDA antagonist, it has been suggested that it
would have efficacy in neuropathic pain. Methadone has
been shown to attenuate mechanical and cold allodynia in
experimental models of both peripheral and central neuro-
pathic pain (18), exhibiting anti-allodynic affects superior to
oxycodone and morphine (19). It has also been shown that
the blockade of NMDA receptors plays an important role in
the analgesic effects observed in experimental models of
peripheral neuropathic pain (20), which may also be related
to its norepinephrine and serotonin reuptake blocker
properties (21). The preferential effect of methadone in
dynamic mechanical allodynia found in the present study
and its correlation with sleep improvement is an original
finding and confirms the findings from experimental
studies. Larger controlled trials of the use of methadone in
neuropathic pain must be performed because it is an
inexpensive opioid that has pharmacological particularities,
such as long half-life and NMDA antagonism that make it
an attractive option to opioids currently available for this
pain syndrome. Placebo use in pain patients frequently
raises ethical concerns. Despite the possible analgesic effect
of methadone to treat PHN a priori, it is not currently
approved as a treatment option for neuropathic pain, and it
is not widely available in Europe or in many Latin American
countries for this indication mainly because of the lack of
clinical evidence attesting to its efficacy, such as this brief
pilot study. Methadone and placebo were added to the
current analgesic regimen of patients who were already
receiving the best pharmacological treatment available at
our institution at the time of the study. Thus, a more
effective neuropathic pain treatment was not withheld
because of participating in this study protocol; both
methadone and placebo were used as an ‘‘add-on’’
treatment. As part of our current ethical recommendations,
all patients who improved while taking methadone were
offered the medication on a long-term treatment basis after
the study ended.
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